- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01140646
Evaluation of SAMe for Hot Flashes (SAMe)
Phase II Evaluation of S-Adenosyl-L-Methionine (SAMe) for the Treatment of Hot Flashes
RATIONALE: S-adenosyl-L-methionine may help relieve hot flashes in women based upon its ability to potentially modulate serotonin.
PURPOSE: This phase II trial is studying the side effects and how well s-adenosyl-L-methionine works in treating hot flashes in women with a history of breast cancer or those who do not wish to take estrogen due to a perceived increased risk of breast cancer.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
I. To evaluate the impact of SAMe on hot flash scores in women with a history of breast cancer or women who do not wish to take estrogen therapy for fear of increased risk of breast cancer.
II. To evaluate the toxicity of SAMe in this study population. III. To evaluate the effect of SAMe using quality-of-life (QOL) measures.
OUTLINE:
During the first week, participants will complete a daily, prospective hot flash diary and complete baseline questionnaires and will not be taking any study medication. After this baseline week, participants will receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with a history of breast cancer (currently without malignant disease) or women who have no history of breast cancer but who wish to avoid estrogen due to a perceived increased risk of breast cancer
- Bothersome hot flashes (defined by their occurrence >= 14 times per week and of sufficient severity to make the patient desire therapeutic intervention)
- Presence of hot flashes for >= 1 month prior to registration
- Life expectancy >= 6 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
- Ability to complete questionnaire(s) by themselves or with assistance
- Negative pregnancy test done =< 7 days prior to registration for women of childbearing potential only
Exclusion Criteria:
- Any of the following current (=< last 4 weeks) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but the patient must have been on a constant dose for >= 4 weeks and must not be expected to stop the medication during the study period): antineoplastic chemotherapy, androgens, estrogens, progestational agents, other herbal supplements, including soy, vitamin E, flaxseed, and megadose vitamins (herbal teas, multivitamins, and vitamin D are allowed), warfarin (1 mg of daily warfarin is allowed for central line patency), medications interacting with SAMe (antidepressants, monoamine oxidase (MAO) inhibitors, meperidine, dextromethorphan, pentazocine, tramadol, gabapentin, and levodopa)
- Pregnant women
- Nursing women
- Women of childbearing potential who are unwilling to employ adequate contraception
- Known allergy to SAMe
- Current use or use within the past 6 months of SAMe
- Clinically significant acute or chronic progressive or unstable neurologic, psychiatric, hepatic, renal, cardiovascular, respiratory, metabolic, or systemic disease precluding participation in the study
- History of bipolar disorder or Parkinsonism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
The first week of the study is a baseline week where data are being collected but study agent is not being taken.
Patients then receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
|
Ancillary studies
Ancillary studies
Other Names:
Given orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Baseline in Average Hot Flash Activity (Score and Frequency)
Time Frame: From baseline to week 7
|
Hot flash score was defined as the number of mild hot flashes for the week plus two times the number of moderate hot flashes plus three times the number of severe hot flashes plus four times the number of very severe hot flashes.
Hot flash frequency was defined as the average number of hot flashes per day for each week.
Week 7 percent of baseline was calculated.
The reduction in hot flash score and frequency can be calculated by subtracting the week 7 percent of baseline from 100 percent.
|
From baseline to week 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 7 for the Side Effect Questionnaire (SEQ)
Time Frame: Baseline and Week 7
|
The side effect questionnaire (SEQ) consists of 15 items on a scale of 0 to 10 with 10 represents worse symptoms.
Each item were reported as individual scores with all scores transposed to a 0-100 point percentage scale where 100 is the best quality of life (QOL) scores.
Change from baseline to week 7 scores was calculated by subtracting the baseline scores from the scores at week 7.
The positive change in scores indicates an improvement in QOL and negative change in scores indicates a decline in QOL.
|
Baseline and Week 7
|
Change From Baseline to Week 7 for the Profile of Mood States (POMS)
Time Frame: Baseline and Week 7
|
The Profile of Mood States (POMS) consists of 30 items on scale of 0 to 4 (0=not at all, 1=a little, 2=moderately, 3=quite a bit and 4=extremely).
The POMS was scored according to its specific scoring algorithm resulting in a total score and six subscale scores (anger/hostility, confusion/bewilderment, depression/dejection, fatigue/inertia, tension/anxiety, and vigor/activity).
All scores were transposed to a 0-100 point percentage scale where 100 is the best quality of life (QOL) scores.
Change from baseline to week 7 scores was calculated by subtracting the baseline scores from the scores at week 7.
The positive change in scores indicates an improvement in QOL and negative change in scores indicates a decline in QOL.
|
Baseline and Week 7
|
Change From Baseline to Week 7 for the Hot Flash Related Daily Interference Scale (HFRDIS)
Time Frame: Baseline and Week 7
|
The Hot Flash Related Daily Interference Scale (HFRDIS) consists of 10 items on scale of 0 to 10 with 0 represents do not interfere and 10 represents completely interferes.
An average of the scores of the 10 individual items was calculated for the HFRDIS total score.
Each individual item were reported as individual scores.
All scores were transposed to a 0-100 point percentage scale where 100 is the best quality of life (QOL) scores.
Change from baseline to week 7 scores was calculated by subtracting the baseline scores from the scores at week 7.
The positive change in scores indicates an improvement in QOL and negative change in scores indicates a decline in QOL.
|
Baseline and Week 7
|
Number of Patients Who Reported Grade 3 Adverse Events
Time Frame: Week 1 to Week 7
|
Adverse events were assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
|
Week 1 to Week 7
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Amit Sood, M.D., Mayo Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC09C4 (Other Identifier: Mayo Clinic Cancer Center)
- NCI-2010-01224 (Registry Identifier: NCI's CTRO)
- 10-001896 (Other Identifier: Mayo Clinic IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hot Flashes
-
Mitsubishi Tanabe Pharma America Inc.CompletedMenopause Hot FlashesUnited States
-
AmgenCompleted
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedTreatment of Menopausal Hot FlashesUnited States
-
University of California, San FranciscoCompleted
-
University of California, San FranciscoCompleted
-
Alison Huang, MDNational Institute on Aging (NIA)Completed
-
University of PennsylvaniaForest LaboratoriesCompleted
-
Liverpool John Moores UniversityBritish Heart FoundationRecruiting
-
Solvay PharmaceuticalsCompletedHot Flushes, Menopause, PostmenopauseUnited States, Canada, Russian Federation
-
Donesta BioscienceSynteractHCRCompleted
Clinical Trials on questionnaire administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden